Corrects March 12 story to fix typographical error in company's name in headline
Overview
US cell therapy developer reported Q4 net loss of $38.8 million
No revenue reported for Q4 as clinical programs advance
Outlook
Company expects 2026 operating cash expense of about $150 mln
Allogene expects GAAP operating expenses in 2026 of about $210 mln
COST MANAGEMENT - Cash runway extended into Q1 2028 due to disciplined expense management and return of $23.7 mln in escrow funds
Result Drivers
PIPELINE INVESTMENT - Net loss driven by continued R&D spending on pivotal ALPHA3 and RESOLUTION clinical trials
The Company had $258.3 million in cash, cash equivalents, and investments as of December 31, 2025
Company press release: ID:nGNX3XqPkn
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 EPS | -$0.17 | ||
Q4 Net Income | -$38.81 mln | ||
Q4 Basic EPS | -$0.17 | ||
Q4 Income From Operations | -$42.40 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", 1 "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Allogene Therapeutics Inc is $7.50, about 185.2% above its March 11 closing price of $2.63
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Comments